Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NRC National Research Corp
- Stocks
- Healthcare
- NASDAQ: NRC
Price (delayed)
$14.09
Market cap
$321.05M
P/E Ratio
13.55
Dividend/share
$0.48
EPS
$1.04
Enterprise value
$383.75M
NRC Health is the leading provider of in-depth customer insights in healthcare.
Highlights
The stock's price to earnings (P/E) is 53% less than its 5-year quarterly average of 28.9 and 21% less than its last 4 quarters average of 17.1
The quick ratio has grown by 42% year-on-year but it has declined by 14% since the previous quarter
National Research's debt has surged by 55% YoY and by 4% QoQ
National Research's equity has decreased by 20% YoY and by 5% QoQ
Key stats
What are the main financial stats of NRC
Market
Valuations
Earnings
Shares outstanding
22.79M
Market cap
$321.05M
Enterprise value
$383.75M
Price to earnings (P/E)
13.55
Price to book (P/B)
10.9
Price to sales (P/S)
2.29
EV/EBIT
10.93
EV/EBITDA
9.31
EV/Sales
2.72
Revenue
$141.3M
Gross profit
$85.16M
Operating income
$35.03M
Net income
$24.21M
EBIT
$35.11M
EBITDA
$41.22M
Free cash flow
$14.94M
Per share
Balance sheet
Liquidity
EPS
$1.04
EPS diluted
$1.03
Free cash flow per share
$0.65
Book value per share
$1.29
Revenue per share
$6.15
TBVPS
$2.9
Total assets
$135.18M
Total liabilities
$105.5M
Debt
$65.21M
Equity
$29.67M
Working capital
-$17.37M
Debt to equity
2.2
Current ratio
0.54
Quick ratio
0.37
Net debt/EBITDA
1.52
Margins
Efficiency
Dividend
EBITDA margin
29.2%
Gross margin
60.3%
Net margin
17.1%
Operating margin
24.8%
Return on assets
18.7%
Return on equity
71.3%
Return on invested capital
47%
Return on capital employed
36%
Return on sales
24.8%
Dividend yield
3.41%
DPS
$0.48
Payout ratio
46.2%
NRC stock price
How has the National Research stock price performed over time
Intraday
-0.21%
1 week
5.94%
1 month
10.34%
1 year
-49.59%
YTD
-20.12%
QTD
10.08%
Financial performance
How have National Research's revenue and profit performed over time
Revenue
$141.3M
Gross profit
$85.16M
Operating income
$35.03M
Net income
$24.21M
Gross margin
60.3%
Net margin
17.1%
NRC's net income is down by 20% YoY and by 2.3% QoQ
National Research's net margin has decreased by 17% YoY
NRC's operating income is down by 12% YoY
National Research's operating margin has decreased by 8% YoY
Price vs fundamentals
How does NRC's price correlate with its fundamentals
Growth
What is National Research's growth rate over time
Valuation
What is National Research stock price valuation
P/E
13.55
P/B
10.9
P/S
2.29
EV/EBIT
10.93
EV/EBITDA
9.31
EV/Sales
2.72
The stock's price to earnings (P/E) is 53% less than its 5-year quarterly average of 28.9 and 21% less than its last 4 quarters average of 17.1
The EPS has declined by 17% year-on-year
NRC's price to book (P/B) is 33% less than its 5-year quarterly average of 16.3 and 17% less than its last 4 quarters average of 13.1
National Research's equity has decreased by 20% YoY and by 5% QoQ
The P/S is 66% lower than the 5-year quarterly average of 6.7 and 26% lower than the last 4 quarters average of 3.1
National Research's revenue has decreased by 4.2% YoY
Efficiency
How efficient is National Research business performance
NRC's return on invested capital is down by 50% year-on-year and by 15% since the previous quarter
NRC's return on equity is up by 30% year-on-year and by 2.9% since the previous quarter
The return on assets has declined by 23% year-on-year and by 5% since the previous quarter
The return on sales has declined by 9% year-on-year
Dividends
What is NRC's dividend history
DPS
$0.48
Dividend yield
3.41%
Payout ratio
46.2%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did National Research financials performed over time
NRC's total assets is 28% greater than its total liabilities
The quick ratio has grown by 42% year-on-year but it has declined by 14% since the previous quarter
NRC's current ratio is up by 32% YoY
National Research's debt is 120% higher than its equity
NRC's debt to equity has soared by 93% YoY and by 10% QoQ
National Research's debt has surged by 55% YoY and by 4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.